Document ID: chunk:federal_register_of_legislation:F2024C00658:reg:9:p5
Version: federal_register_of_legislation:F2024C00658
Segment Type: reg
Provision Reference: reg 9 (pt 5/7)
Character Range: 19013–22589

Note: dyslipidaemia is defined in the Schedule 1 - Dictionary.
(45)      having an upper respiratory tract infection, including sinusitis, within the 4 weeks before clinical onset;
(46)      for brain ischaemia only, being treated with intravenous immunoglobulin within the 72 hours before clinical onset;
(47)      for brain ischaemia only, taking combined oral estrogen-progestogen contraception for a continuous period of at least 21 days, within the 4 weeks before clinical onset;
(48)      for brain ischaemia only, taking hormone replacement therapy for a continuous period of at least 21 days within the 2 years before clinical onset;
Note: hormone replacement therapy is defined in the Schedule 1 - Dictionary.
(49)      for brain ischaemia only, taking tamoxifen for a continuous period of at least the 21 days before clinical onset;
(50)      for brain ischaemia only, having carotid artery disease, or occlusion or stenosis of the vertebral artery, basilar artery, aortic arch or ascending aorta due to atherosclerosis, fibromuscular dysplasia, dissection or other pathological process involving that artery, at the time of clinical onset;
(51)      for brain ischaemia only, having a subarachnoid haemorrhage within the 2 weeks before clinical onset;
(52)      for brain ischaemia only, having one of the following hypercoagulable states at the time of clinical onset:
            (a)          acquired activated protein C resistance;
            (b)          acquired antithrombin III deficiency;
            (c)          acquired dysfibrinogenaemia;
            (d)          acquired protein C deficiency;
            (e)          acquired protein S deficiency;
            (f)           antiphospholipid antibody syndrome;
            (g)          disseminated intravascular coagulation;
            (h)          haemolytic uraemic syndrome;
            (i)            heparin-induced thrombocytopaenia;
            (j)            hyperfibrinogenaemia;
            (k)          hyperproteinaemia;
            (l)            hyperviscosity syndrome;
            (m)        chronic idiopathic thrombocytopaenic purpura or immune thrombocytopaenia;
            (n)          myeloma;
            (o)          myeloproliferative disease;
            (p)          nephrotic syndrome;
            (q)          paroxysmal nocturnal haemoglobinuria; or
            (r)           thrombocytosis;
(53)      for brain ischaemia only, experiencing an acute hypotensive episode within the 24 hours before clinical onset;
Note: acute hypotensive episode is defined in the Schedule 1 - Dictionary.
(54)      for brain ischaemia only, having sleep apnoea at the time of clinical onset;
(55)      undergoing a course of therapeutic radiation for cancer, where the head, neck or mediastinum was in the field of radiation, before clinical onset;
(56)      having received a cumulative equivalent dose of at least 1 sievert of ionising radiation to the head, neck or mediastinum before the clinical onset;
Note: cumulative equivalent dose is defined in the Schedule 1 - Dictionary.
(57)      for brain ischaemia only, having hyperhomocysteinaemia at the time of clinical onset;
(58)      for brain ischaemia only, having one of the following traumatic injuries to the neck or the base of the skull within the 4 weeks before clinical onset:
(a)          a non-penetrating injury, involving extension, rotation, hyperflexion or compression of the neck;
(b)          an injury resulting in fracture or dislocation of the cervical spine;
(c)          a penetrating injury to the neck or